Weighing the risks and benefits of chronic opioid therapy

American Family Physician

Volumn 93, Issue 12, 2016, Pages 982-990

  Lembke, Anna ^a   Humphreys, Keith ^a,b   Newmark, Jordan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; FENTANYL; HYDROCODONE; METHADONE; MORPHINE; NALOXONE; OPIATE; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ABDOMINAL PAIN; ADDICTION; ARTICLE; BEHAVIOR CHANGE; BREATHING DISORDER; CARDIOVASCULAR DISEASE; CHRONIC OPIOID THERAPY; CHRONIC PAIN; COMORBIDITY; CONSTIPATION; DEPRESSION; DRUG DEPENDENCE; DRUG MISUSE; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERANCE; DRUG USE; DSM-5; HEART FAILURE; HUMAN; HYPERALGESIA; LUNG DISEASE; PATIENT EDUCATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SLEEP DISORDERED BREATHING; ACUTE PAIN; CLINICAL PRACTICE; MALE; MEDICAL EDUCATION; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINE; STANDARDS; UNITED STATES;

ACUTE PAIN; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC PAIN; DRUG OVERDOSE; EDUCATION, MEDICAL, CONTINUING; HUMANS; MALE; NALOXONE; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RISK ASSESSMENT; UNITED STATES;

EID: 84974785089     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Martin BC, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med. 2011;26(12):1450-1457.
2. Chen J, Humphreys K, Shah NH, Lembke A. Distribution of opioids by different types of Medicare prescribers. JAMA Intern Med. 2016; 176(2): 259-261.
3. Hegmann KT, Weiss MS, Bowden K, et al.; American College of Occupational and Environmental Medicine. ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med. 2014;56(12):e143-e159.
4. Chou R, Deyo R, Devine B, et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment no. 218. Rockville, Md.: Agency for Healthcare Research and Quality; 2014.
5. American Academy of Family Physicians. Pain management and opioid abuse: a public health concern. http://www.aafp.org/dam/AAFP/ documents/patient_care/pain_management/opioid-abuse-positionpaper.pdf. Accessed February 26, 2016.
6. Shaw K, Fudin J. Evaluation and comparison of online equianalgesic opioid dose conversion calculators. Pract Pain Manag. Updated October 28, 2014. http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/evaluation-comparison-online-equianalgesicopioid-dose-conversion. Accessed March 8, 2016.
7. Berdine HJ, Nesbit SA. Equianalgesic dosing of opioids. J Pain Palliat Care Pharmacother. 2006;20(4):79-84.
8. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity [published correction appears in Pain Med. 2012;13(12):1667]. Pain Med. 2012;13(4):562-570.
9. Kuryshev YA, Bruening-Wright A, Brown AM, Kirsch GE. Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels. J Cardiovasc Pharmacol. 2010;56(4):420-430.
10. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010; 152(2):85-92.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
12. Weisner CM, Campbell CI, Ray GT, et al. Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain. 2009;145(3):287-293.
13. Webster LR, Webster RM. Predicting aberrant behaviors in opioidtreated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
14. Prescription Drug Monitoring Program Center of Excellence at Brandeis University. Briefing on PDMP effectiveness. September 2014. http://www.pdmpexcellence.org/content/briefings. s
15. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1-49.
16. Pade PA, Cardon KE, Hoffman RM, Geppert CM. Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model. J Subst Abuse Treat. 2012;43(4):446-450.
17. Ray WA, Chung CP, Murray KT, Cooper WO, Hall K, Stein CM. Out-ofhospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med. 2015;175(3):420-427.
18. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioidinduced constipation in advanced illness. N Engl J Med. 2008; 358(22): 2332-2343.
19. Drossman DA, Morris CB, Edwards H, et al. Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. Am J Gastroenterol. 2012;107(9):1426-1440.
20. Madadi P, Persaud N. Suicide by means of opioid overdose in patients with chronic pain. Curr Pain Headache Rep. 2014;18(11):460.
21. Margari F, Lorusso M, Matera E, et al. Aggression, impulsivity, and suicide risk in benign chronic pain patients-a cross-sectional study. Neuropsychiatr Dis Treat. 2014;10:1613-1620.
22. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmüller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab. 2005;90(1):203-206.
23. Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain. 2010;26(5):374-380.
24. Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic noncancer pain. Neurogastroenterol Motil. 2010;22(4):424-430, e96.
25. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011; 14(2): 145-161.
26. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain. 2006;7(1):43-48.
27. Crofford LJ. Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nat Rev Rheumatol. 2010;6(4):191-197.
28. Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12(3):679-684.
29. Boscarino JA, Rukstalis MR, Hoffman SN, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. J Addict Dis. 2011; 30(3): 185-194.
30. Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain. 2007;11(5):490-518.
31. Sweis G, Huffman K, Shella E, Scheman J. Longitudinal treatment outcomes of patients with comorbid chronic pain and substance dependence within a multidisciplinary chronic pain program [abstract]. J Pain. 2012;13(4 suppl):S107.
32. Naliboff BD, Wu SM, Schieffer B, et al. A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. J Pain. 2011;12(2):288-296.
33. Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Opioid use behaviors, mental health and pain—development of a typology of chronic pain patients. Drug Alcohol Depend. 2009;104(1-2):34-42.
34. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):557-564.
35. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961-972.
36. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
37. Humphreys K. An overdose antidote goes mainstream. Health Aff (Millwood). 2015;34(10):1624-1627.
38. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686-691.
39. Binswanger IA, Nowels C, Corsi KF, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7:3.
40. Mogri M, Desai H, Webster L, Grant BJ, Mador MJ. Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep Breath. 2009;13(1):49-57.
41. Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing [published correction appears in J Clin Sleep Med. 2007;3(6):table of contents]. J Clin Sleep Med. 2007;3(5):455-461.
42. Holzer P. Opioid antagonists for prevention and treatment of opioidinduced gastrointestinal effects. Curr Opin Anaesthesiol. 2010; 23(5): 616-622.
43. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347-1354.
44. Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26(10):1386-1395.
45. Szigethy E, Schwartz M, Drossman D. Narcotic bowel syndrome and opioid-induced constipation. Curr Gastroenterol Rep. 2014;16(10):410.
46. Kurlander JE, Drossman DA. Diagnosis and treatment of narcotic bowel syndrome. Nat Rev Gastroenterol Hepatol. 2014;11(7):410-418.
47. Low Y, Clarke CF, Huh BK. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med J. 2012; 53(5): 357-360.
48. Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP. Age-dependent opioid escalation in chronic pain patients. Anesth Analg. 2005; 100(6): 1740-1745.
49. Portenoy RK, Foley KM. Chronic use of opioid analgesics in nonmalignant pain: report of 38 cases. Pain. 1986;25(2):171-186.
50. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302(2):123.
51. Scherrer JF, Svrakic DM, Freedland KE, et al. Prescription opioid analgesics increase the risk of depression. J Gen Intern Med. 2014;29(3):491-499.
52. Karch DL, Logan J, Patel N; Centers for Disease Control and Prevention (CDC). Surveillance for violent deaths-National Violent Death Reporting System, 16 states, 2008. MMWR Surveill Summ. 2011;60(10):1-49.
53. Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5(3):684-692.
54. Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31(1):98-132.
55. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005;95(7):915-918.
56. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction. 2007;102(2):289-300.
57. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93(9):1051-1055.
58. Modesto-Lowe V, Brooks D, Petry N. Methadone deaths: risk factors in pain and addicted populations. J Gen Intern Med. 2010;25(4):305-309.
59. Carman WJ, Su S, Cook SF, Wurzelmann JI, McAfee A. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf. 2011;20(7):754-762.
60. Berland D, Rodgers P. Rational use of opioids for management of chronic nonterminal pain. Am Fam Physician. 2012;86(3):252-258.